Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin

Platelets

Volumn 19, Issue 6, 2008, Pages 415-427

  Khandoga, A L ^a   Fujiwara, Y ^b   Goyal, P ^a   Pandey, D ^a   Tsukahara, R ^b   Bolen, A ^b   Guo, H ^b   Wilke, N ^a   Liu, J ^b   Valentine, W J ^b   Durgam, G G ^b   Miller, D D ^b   Jiang, G ^c   Prestwich, G D ^c   Tigyi, G ^b   Siess, W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Agonist; Albumin; Antagonist; G protein coupled receptor; Lysophosphatidic acid

Indexed keywords

ALBUMIN; CYCLIC AMP; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; LYSOPHOSPHATIDIC ACID RECEPTOR 4; LYSOPHOSPHATIDIC ACID RECEPTOR 5; LYSOPHOSPHATIDIC ACID RECEPTOR 7; MESSENGER RNA; N PALMITOYLSERINE PHOSPHORIC ACID; N PALMITOYLTYROSINE PHOSPHORIC ACID; PHOSPHATIDIC ACID; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; THROMBOCYTE SHAPE;

ANIMALS; BLOOD PLATELETS; CELL SHAPE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MODELS, CHEMICAL; PHOSPHATIDIC ACIDS; PLATELET ACTIVATION; RATS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 54249134426     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100802220468     Document Type: Article

References (35)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
2. Siess W, Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem 2004;92:1086-1094.
3. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-1494.
4. Weidtmann A, Scheithe R, Hrboticky N, Pietsch A, Lorenz R, Siess W. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler Thromb Vasc Biol 1995;15:1131-1138.
5. Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, Bittolo-Bon G. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996;16:784-793.
6. Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003;108:741-747.
7. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 1999;96:6931-6936.
8. Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 2006;12:65-75.
9. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 2002;277:21197-21206.
10. Chen X, Yang XY,Wang ND, Ding C, Yang YJ, You ZJ, Su Q, Chen JH. Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 2003;63:497-503.
11. Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 1992;267:21360-21367.
12. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002;1582:204-215.
13. Meyer zu Heringdorf D, Jakobs KH. Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007;1768:923-940.
14. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR,Moolenaar W, Pyne S, Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002;54:265-269.
15. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003;278:25600-25606.
16. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589-23597.
17. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007;363:861-866.
18. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, Betz RC. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 2008;40:329-334.
19. Motohashi K, Shibata S, Ozaki Y, Yatomi Y, Igarashi Y. Identification of lysophospholipid receptors in human platelets: The relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett 2000;468:189-193.
20. Amisten S, Braun OO, Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008;122:47-57.
21. Pamuklar Z, Lee JS, Cheng HY, Panchatcharam M, Steinhubl S, Morris AJ, Charnigo R, Smyth SS. Individual heterogeneity in platelet response to lysophosphatidic acid. Evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol 2008;28:555-561.
22. An S, Bleu T, Zheng Y, Goetzl EJ. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. Mol Pharmacol 1998;54:881-888.
23. Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, Parrill A, Tigyi G. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J Biol Chem 2005;280:35038-35050.
24. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 2000;478:159-165.
25. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, Tigyi G, Prestwich GD. alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. Chem Med Chem 2007;2:679-690.
26. Durgam GG, Tsukahara R, Makarova N, Walker MD, Fujiwara Y, Pigg KR, Baker DL, Sardar VM, Parrill AL, Tigyi G, Miller DD. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg Med Chem Lett 2006;16:633-640.
27. Liliom K, Bittman R, Swords B, Tigyi G. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. Mol Pharmacol 1996;50:616-623.
28. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A, Hanahan DJ. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta 1999;1440:194-204.
29. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, Owman C, Sillard R, Leeb-Lundberg LM, Olde B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 2006;318:619-628.
30. Lee CW, Rivera R, Dubin AE, Chun J. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 2007;282:4310-4317.
31. Haseruck N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and P2Y12 receptors. Blood 2004;103:2585-2592.
32. Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 2002;523:187-192.
33. Schumacher KA, Classen HG, Spath M. Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: Identity with substances in aged serum (DAS). Thromb Haemost 1979;42:631-640.
34. Tokumura A, Sinomiya J, Kishimoto S, Tanaka T, Kogure K, Sugiura T, Satouchi K, Waku K, Fukuzawa K. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem J 2002;365:617-628.
35. Thumser AE, Voysey JE, Wilton DC. The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin. Biochem J 1994;301(Pt 3):801-806.